TUG1 showed a protective effect on intestinal tissue, both in-vivo and in-vitro, in ulcerative colitis by inhibiting inflammation-induced ROS and pro-inflammatory cytokines through targeting miR-142-3p and enhancing SOCS1 production (Han et al., 2020) (Table 1). Here, SOCS1 is linked to ulcerative colitis.